• Chimeric Activin A/BMP7 protein with over 30x higher activity compared to natural BMP7
• Current preclinical data indicate DRT-101 potential as a first-in-class DMOAD
• Additional efficacy and safety studies to complete an IND-enabling package are underway
• Target 2026 IND submission (Korea) and subsequent submissions to other regulatory agencies to follow (EU, US)
